Victor Chong

Company: Clearside Biomedical

Job title: Chief Medical Officer & Executive Vice President

Seminars:

Audience Discussion: Optimizing Clinical Trial Design & Navigating Regulatory Landscape for Wet AMD & Diabetic Eye Disease Therapies 8:45 am

Part 1: Diabetic Eye Disease Part 2: Wet AMD Moderated by: Michael Tolentino, Chief Innovation Officer, Aviceda TherapeuticsRead more

day: Day One

Transforming wAMD Treatment: Long-Lasting, Flexible Dosing with Suprachoroidal TKI Delivery 8:00 am

Address the high treatment burden of current anti-VEGF therapies for wAMD, highlighting the need for more sustainable and less frequent treatment but maintain the flexibility of anti-VEGF biologics Explore the benefits of TKIs in wAMD management, focusing on their pan-VEGF receptors blockage, extended drug delivery while acknowledging the limitations of current intravitreal anti-VEGF due to…Read more

day: Day One